China Universal Asset Management Co., Ltd. Immuno Gen, Inc. Transaction History

China Universal Asset Management Co., Ltd.

$893 Million
Q3 2024

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 May 21, 2024	BUY	$12.46 - $29.95 $385,774 - $927,281	30,961 New	30,961 $917,000
Q4 2023 Jan 23, 2024	BUY	$12.46 - $29.95 $306,216 - $736,051	24,576 Added 384.9%	30,961 $918,000
Q3 2023 May 21, 2024	BUY	$14.09 - $19.87 $42,692 - $60,206	3,030 Added 90.31%	6,385 $101,000
Q3 2023 Oct 30, 2023	BUY	$14.09 - $19.87 $42,692 - $60,206	3,030 Added 90.31%	6,385 $101,000
Q2 2023 May 21, 2024	BUY	$3.75 - $20.05 $1,365 - $7,298	364 Added 12.17%	3,355 $63,000
Q2 2023 Jul 27, 2023	BUY	$3.75 - $20.05 $1,365 - $7,298	364 Added 12.17%	3,355 $63,000
Q1 2023 May 21, 2024	BUY	$3.67 - $4.92 $2,748 - $3,685	749 Added 33.41%	2,991 $11,000
Q1 2023 Apr 27, 2023	BUY	$3.67 - $4.92 $2,748 - $3,685	749 Added 33.41%	2,991 $11,000
Q4 2022 May 21, 2024	BUY	$4.55 - $6.31 $10,201 - $14,147	2,242 New	2,242 $11,000
Q4 2022 Jan 31, 2023	BUY	$4.55 - $6.31 $796 - $1,104	175 Added 8.47%	2,242 $11,000
Q3 2022 Oct 21, 2022	BUY	$4.48 - $6.47 $9,260 - $13,373	2,067 New	2,067 $10,000

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account